Michael Nuoqing Yi
Chief Investment Officer at Hillhouse Investment Management Ltd. (Invest)
Profile
Michael Nuoqing Yi has worked as a Director at Sironax Ltd.
and as a Co-Chief Investment Officer at Hillhouse Investment Management Ltd.
(Invest).
Michael Nuoqing Yi active positions
| Companies | Position | Start |
|---|---|---|
Hillhouse Investment Management Ltd. (Invest)
 Hillhouse Investment Management Ltd. (Invest) Investment ManagersFinance Hillhouse Capital Management Ltd. (Hillhouse Capital) is a Private Equity/Venture Capital firm, a subsidiary of Hillhouse Capital Group Ltd. founded in 2005 by Lei Zhang. The firm is headquartered in Hong Kong. | Chief Investment Officer | - |
Sironax Ltd.
 Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Hillhouse Investment Management Ltd. (Invest)
Hillhouse Investment Management Ltd. (Invest) Investment ManagersFinance Hillhouse Capital Management Ltd. (Hillhouse Capital) is a Private Equity/Venture Capital firm, a subsidiary of Hillhouse Capital Group Ltd. founded in 2005 by Lei Zhang. The firm is headquartered in Hong Kong. | Finance |
Sironax Ltd.
Sironax Ltd. Pharmaceuticals: MajorHealth Technology Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research. | Health Technology |
- Stock Market
- Insiders
- Michael Nuoqing Yi
